羚锐制药(600285)

净利润 + 每股收益

Created with Highcharts 9.1.0

03-3112-3109-3006-30036900.81.62.4

净利润(亿元) 每股收益(元)

    截至2025年第一季度实现净利润2.17亿元，每股收益0.38元。

股东权益 + 未分配利润

Created with Highcharts 9.1.0

03-3112-3109-3006-3001224361517.52022.5

股东权益(亿元) 未分配利润(亿元)

    截至2025年第一季度最新股东权益334386.85万元，未分配利润212030.33万元。

总资产 + 负债

Created with Highcharts 9.1.0

03-3112-3109-3006-30020406019202122

总资产(亿元) 负债(亿元)

    截至2025年第一季度最新总资产541089.58万元，负债206702.73万元。

利润表 报告期2025-03-312024-12-312024-09-302024-06-30营业总收入1,020,755,870.553,500,831,286.922,759,116,202.141,906,007,173.3营业总成本780,335,122.232,768,148,768.852,132,955,810.671,454,748,169.02营业利润253,684,137.59810,301,684.55662,676,665.58476,716,553.34利润总额253,668,892.56827,572,996.86665,105,059.05479,096,650.48净利润216,733,789.1722,584,691.99573,907,880413,114,865.4其他综合收益6,311,122.23-52,945,072.92-49,302,213.98-56,954,231.11综合收益总额223,044,911.33669,639,619.07524,605,666.02356,160,634.29 资产负债表 报告期2025-03-312024-12-312024-09-302024-06-30流动资产合计2,004,404,855.72,458,038,247.112,262,062,502.12,099,554,692.35非流动资产合计3,406,490,925.222,558,804,960.622,623,500,075.952,614,416,820.84资产总计5,410,895,780.925,016,843,207.734,885,562,578.054,713,971,513.19流动负债合计1,986,108,168.891,874,335,175.061,917,993,701.61,939,062,284.83非流动负债合计80,919,127.4662,215,968.6765,980,773.5163,927,964.23负债合计2,067,027,296.351,936,551,143.731,983,974,475.112,002,990,249.06归属于母公司股东权益合计3,311,522,505.913,072,526,287.292,893,837,629.182,703,211,333.73股东权益合计3,343,868,484.573,080,292,0642,901,588,102.942,710,981,264.13负债和股东权益合计5,410,895,780.925,016,843,207.734,885,562,578.054,713,971,513.19 现金流量表 报告期2025-03-312024-12-312024-09-302024-06-30经营活动现金流入小计903,232,099.553,924,835,712.292,656,515,780.871,835,882,538.51经营活动现金流出小计785,616,199.433,048,971,479.162,306,466,328.621,545,283,321.58经营活动产生的现金流量净额117,615,900.12875,864,233.13350,049,452.25290,599,216.93投资活动现金流入小计159,012,139.42465,877,124.381,132,711,885.05513,778,335.52投资活动现金流出小计944,785,928.441,131,709,447.721,750,214,149.761,122,842,238.19投资活动产生的现金流量净额-785,773,789.02-665,832,323.34-617,502,264.71-609,063,902.67筹资活动现金流入小计11,340,271.8984,193,548.6419,592,190.8325,705,891.33筹资活动现金流出小计617,588.12556,131,430.6469,975,832.3470,622,535.02筹资活动产生的现金流量净额10,722,683.77-471,937,881.96-450,383,641.47-444,916,643.69汇率变动对现金及现金等价物的影响-12,982.27,770.61-3,101.422,157.48现金及现金等价物净增加额-657,448,187.33-261,898,201.56-717,839,555.35-763,379,171.95期末现金及现金等价物余额570,929,618.671,228,377,806772,436,452.21726,896,835.61

最新报告期：2025-05-02

研究机构分析师预测每股收益(元)更新日2025年2026年2027年兴业证券孙媛媛,董晓洁1.481.691.932025-05-02开源证券余汝意1.471.681.892025-05-01信达证券唐爱金,章钟涛1.471.681.942025-04-29浙商证券丁健行,吴天昊1.491.721.982025-04-28国金证券袁维1.481.671.892025-04-27

网址：羚锐制药(600285) http://c.mxgxt.com/news/view/1064492

相关内容

演员陈锐左羚简历
彭羚
百雀羚小绿瓶携手张云雷诠释“百雀羚国风大使”
哈哈哈，被命令控制，单膝下跪成了苏易水最后的尊严? 出处：羚了个羊
Apple Music 上的歌单“彭羚代表作”
羚邦集团(02230)附属拟认购香港新晋影视制作公司S11经扩大10%股权
关于百雀羚
律师谈百雀羚代言人王一博是否受牵连 明星代言风险再引关注
百雀羚水嫩精纯明星眼霜
百雀羚数字媒介第二轮沟通方案.pptx

随便看看